Answers are grounded in this paper and cite their sources.
Recent data suggest that the overall survival (OS) and progression-free survival (PFS) observed in RW patients with mNSCLC receiving IO regimens may be shorter than that seen in randomised clinical trials (RCTs). This retrospective, observational study describes rwOS and rwPFS (overall and by PD-L1 expression) compared with the outcomes observed in RCTs in patients with mNSCLC.
No takes yet. Share an insight, caveat, or question.
Peters et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: